Generate Biomedicines Inc. is a biotechnology company pioneering the field of generative biology to create breakthrough medicines. Founded by Flagship Pioneering in 2018, the company operates at the intersection of machine learning, biological engineering, and high-throughput experimental biology. Unlike traditional drug discovery, which often relies on screening existing libraries or natural molecules, Generate Biomedicines uses its proprietary 'Generate Platform' to programmatically design de novo protein therapeutics. The Generate Platform is built upon a sophisticated computational engine that has learned the fundamental principles of protein structure and function by analyzing vast datasets of biological sequences. This allows the company to design proteins with specific, desired characteristics—such as binding affinity, stability, and potency—across various modalities, including antibodies, peptides, and enzymes. By treating drug discovery as an engineering challenge, the company aims to increase the probability of clinical success and drastically shorten development timelines. Generate Biomedicines' therapeutic pipeline spans multiple high-impact areas, including oncology, immunology, and infectious diseases. The company is led by CEO Mike Nally and a team of experts in both computational science and drug development. Through its innovative approach, Generate Biomedicines seeks to transform the pharmaceutical industry by moving from a model of serendipitous discovery to one of intentional, AI-driven design, ultimately delivering more effective treatments to patients worldwide.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!